Retrospective Analysis of the Consequences of Acid Suppressive Therapy on Ketoconazole Efficacy in Advanced Castration-Resistant Prostate Cancer

Abstract

Spanish

French

Background:

The area under the curve of a single ketoconazole dose has been shown to decrease significantly when administered with acid suppressive therapy. No published studies have examined the clinical impact of concurrent ketoconazole and acid suppressive therapy in patients with castration-resistant prostate cancer (CRPC).

Objective:

To evaluate the effect of acid suppressive therapy on prostate-specific antigen (PSA) response rate in CRPC patients receiving ketoconazole.

Methods:

This retrospective study evaluated CRPC patients treated with ketoconazole 3 times daily between January 1, 1999, and September 30, 2009. Patients included in the analysis had failed androgen deprivation therapy, and were subsequently initiated on ketoconazole. Response (PSA decline ≥50% maintained ≥4 weeks) was evaluated in patients receiving ketoconazole with (group 1 [G1]) or without (group 2 [G2]) concurrent acid suppressive therapy.

Results:

Thirty patients (G1: 11 patients; G2: 19 patients) were included in the analysis. Mean age in G1 and G2 was 71.8 and 69.6 years, respectively. Most patients had received prior therapy with an antiandrogen (90.9% G1; 100% G2) and fewer patients received antiandrogen withdrawal therapy (27.3% G1; 21.1% G2). Median baseline PSA was 109.4 (G1) and 86.9 ng/mL (G2) (p = 0.55). Median duration of ketoconazole was 7.2 months in G1 and 5.8 months in G2 (p = 0.09). Ketoconazole adherence was 82% (G1) and 100% (G2). Median duration of concurrent acid suppressive therapy was 3.8 months (range 2.0–20.4) in G1. PSA response (72.7% and 47.4%; p = 0.26) and time to PSA response (1.2 vs 0.9 mo; p = 0.53) were statistically similar between G1 and G2, respectively. Median progression free survival was higher in G1 (11.5 vs 6.9 months in G2; p = 0.047).

Conclusions:

Use of concurrent acid suppressive therapy and ketoconazole in CRPC patients did not decrease PSA response rate, and progression free survival was unexpectedly higher compared with the non–acid suppressive therapy group. Larger studies are needed to verify the clinical impact of acid suppressive therapy in combination with ketoconazole.

Keywords

drug interactions ketoconazole prostate neoplasms proton pump inhibitors

Get full access to this article

View all access options for this article.

References

Statistics for 2010. American Cancer Society. www.cancer.org (accessed 2010 Jul 4).

The NCCN Clinical Practice Guidelines in oncology prostate cancer (version 1.2010). www.nccn.org/professionals/physician_gls/PDF/prostate.pdf (accessed 2010 Mar 18).

Pont

, Williams

, Azhar

. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982;142:2137–40.

Reid

, Attard

, Barrie

, de Bono

. CYP17 as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5:610–20.

Ketoconazole. In: DRUGDEX system. Greenwood Village, CO: Thomson Healthcare. Updated periodically (accessed 2010 Mar 4).

Small

, Halabi

, Dawson

. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025–33.

Small

, Baron

, Bok

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 1997;80:1755–9.

Small

, Baron

, Fippin

, Apodaca

Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 1997;157:1204–7.

Lelawongs

, Barone

, Colaizzi

. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 1988;7:228–35.

10.

Chin

, Loeb

, Fong

. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 1995;39:1671–5.

11.

Piscitelli

, Goss

. Wilton

, D'andrea

, Goldstein

, Schentag

. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 1991;35:1765–71.

12.

IMS study finds decline in prescription drug market growth. Drug Store News. Findarticles.com (accessed 2009 Aug 25).

13.

Nakabayashi

, Xie

, Regan

, Jackman

, Kantoff

, Oh

. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 2006;107:975–81.

14.

Wilkinson

, Chodak

An evaluation of intermediate-dose ketoconazole in hormone refractory prostate cancer. Eur Urol 2004;45:581–4.

15.

Ngo

, Yeo

, Wong

, Tay

. Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and the Cancer Institute, Singapore. Ann Acad Med Singapore 2007;36:811–4.

16.

Tannock

, de Wit

, Berry

. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.

17.

Howden

, Forrest

, Reid

. Effects of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 1984;25:707–10.

18.

Lind

, Cederberg

, Ekenved

, Hagland

, Olbe

Effect of omeprazole—a gastric proton pump inhibitor—on pentagastrin stimulated acid secretion in man. Gut 1983;24:270–6.

19.

Bubley

, Carducci

, Dahut

. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461–7.

20.

Talebi

, Manoharan

, Soloway

, Singal

Efficacy of high-dose ketoconazole in castration-resistant, metastatic prostate cancer patients previously treated with docetaxel chemotherapy: single institution retrospective review (abstract 163). J Clin Oncol 2010;28(suppl): e15151.

21.

Galsky

, Simon

, Sonpavde

. Ketoconazole retains activity in patients with docetaxel refractory prostate cancer. 2009;20:965–6.